Oarsman Outlook: July 2020

The first half of 2020 will be remembered as one of the most remarkable investment periods in history.  Following gut-wrenching plunges of 35% or more in a matter of weeks beginning in late February, nearly all asset categories staged equally astonishing recoveries...

Oarsman Outlook: April 2020

Pandemic 2020: One Month In The COVID-19 pandemic, an archetypal “black swan” event, has upended the global economy and financial markets (not to mention our daily lives). As the implications of the crisis came into focus in late February, swaths of the financial...

Bristol-Meyers Squibb (BMY)

Market Cap $131.1 billion 2020E 2021E 2022E Price as of 04/07/20 $56.88 EPS 6.15 7.39 7.98 Dividend 2.97% P/E 9.4x 7.8x 7.3x Avg Price Target $75.00 52-week Range $42.48 – $68.34   Overview Bristol-Meyers Squibb (BMY) is a pharmaceutical company that has a...

Oarsman Outlook: January 2020

The final three months of 2019 featured robust results from nearly all investment categories.  The advance was paced by 8% to 10% gains by both large- and small-company U.S. stocks.  Overseas, developed and frontier markets rose a bit less, though the emerging-market...

Oarsman Capital Announces the Milestone Series

Oarsman Capital introduces the Milestone Series.  The Milestone Series targets important financial considerations based on client age.  Oarsman clients receive a Milestone flyer when they reach a financially important milestone birthday with information specific to...